<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://www.jem.org">
<title>Current Print Issue</title>
<link>http://www.jem.org</link>
<description>Journal of Experimental Medicine RSS feed -- current issue</description>
<prism:eIssn>1540-9538</prism:eIssn>
<prism:coverDisplayDate>May 12 2008 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>Journal of Experimental Medicine</prism:publicationName>
<prism:issn>0022-1007</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/i12?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/i13?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/i14?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/996?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/998?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/998-a?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/999?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/999-a?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/999-b?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1000?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1003?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1009?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1019?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1029?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1037?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1049?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1063?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1077?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1087?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1099?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1109?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1121?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1133?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1145?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1155?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1173?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1187?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1201?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1213?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1227?rss=1" />
  <rdf:li rdf:resource="http://www.jem.org/cgi/content/short/205/5/1243?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://www.jem.org/icons/banner/title.gif" />
</channel>

<image rdf:about="http://www.jem.org/icons/banner/title.gif">
<title>Journal of Experimental Medicine</title>
<url>http://www.jem.org/icons/banner/title.gif</url>
<link>http://www.jem.org</link>
</image>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/i12?rss=1">
<title><![CDATA[Cholesterol Promotes Hemifusion and Pore Widening in Membrane Fusion Induced by Influenza Hemagglutinin]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/i12?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Biswas, S., Yin, S.-R., Blank, P. S., Zimmerberg, J.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/JEM2055OIA12</dc:identifier>
<dc:title><![CDATA[Cholesterol Promotes Hemifusion and Pore Widening in Membrane Fusion Induced by Influenza Hemagglutinin]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>i12</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>i12</prism:startingPage>
<prism:section>From J. Gen. Physiol.</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/i13?rss=1">
<title><![CDATA[Prion protein attenuates excitotoxicity by inhibiting NMDA receptors]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/i13?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Khosravani, H., Zhang, Y., Tsutsui, S., Hameed, S., Altier, C., Hamid, J., Chen, L., Villemaire, M., Ali, Z., Jirik, F. R., Zamponi, G. W.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/JEM2055OIA13</dc:identifier>
<dc:title><![CDATA[Prion protein attenuates excitotoxicity by inhibiting NMDA receptors]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>i13</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>i13</prism:startingPage>
<prism:section>From the JCB</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/i14?rss=1">
<title><![CDATA[All quiet on the neuronal front: NMDA receptor inhibition by prion protein]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/i14?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Steele, A. D.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/JEM2055OIA14</dc:identifier>
<dc:title><![CDATA[All quiet on the neuronal front: NMDA receptor inhibition by prion protein]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>i14</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>i14</prism:startingPage>
<prism:section>From the JCB</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/996?rss=1">
<title><![CDATA[You wrote it; you own it!]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/996?rss=1</link>
<description><![CDATA[
<p>Authors of papers published in Rockefeller University Press journals (<I>The Journal of Cell Biology</I>, <I>The Journal of Experimental Medicine</I>, or <I>The Journal of General Physiology</I>) now retain copyright to their published work. This permits authors to reuse their own work in any way, as long as they attribute it to the original publication. Third parties may use our published materials under a Creative Commons license, six months after publication.</p>
]]></description>
<dc:creator><![CDATA[Hill, E., Rossner, M.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20080744</dc:identifier>
<dc:title><![CDATA[You wrote it; you own it!]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>997</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>996</prism:startingPage>
<prism:section>EDITORIAL</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/998?rss=1">
<title><![CDATA[New targets for aspirin]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/998?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Bashyam, H.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.2055iti2</dc:identifier>
<dc:title><![CDATA[New targets for aspirin]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>998</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>998</prism:startingPage>
<prism:section>In This Issue</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/998-a?rss=1">
<title><![CDATA[Spreading instead of growing]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/998-a?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Bashyam, H.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.2055iti5</dc:identifier>
<dc:title><![CDATA[Spreading instead of growing]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>998</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>998</prism:startingPage>
<prism:section>In This Issue</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/999?rss=1">
<title><![CDATA[Weakening HIV]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/999?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Bashyam, H.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.2055iti1</dc:identifier>
<dc:title><![CDATA[Weakening HIV]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>999</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>999</prism:startingPage>
<prism:section>In This Issue</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/999-a?rss=1">
<title><![CDATA[A trick presentation]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/999-a?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Bashyam, H.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.2055iti3</dc:identifier>
<dc:title><![CDATA[A trick presentation]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>999</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>999</prism:startingPage>
<prism:section>In This Issue</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/999-b?rss=1">
<title><![CDATA[Dangers of restocking T cells]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/999-b?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Bashyam, H.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.2055iti4</dc:identifier>
<dc:title><![CDATA[Dangers of restocking T cells]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>999</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>999</prism:startingPage>
<prism:section>In This Issue</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1000?rss=1">
<title><![CDATA[Susan Allen: Confronting HIV in Africa]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1000?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Bashyam, H.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.2055pi</dc:identifier>
<dc:title><![CDATA[Susan Allen: Confronting HIV in Africa]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1001</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1000</prism:startingPage>
<prism:section>PEOPLE &amp; IDEAS</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1003?rss=1">
<title><![CDATA[Crippling HIV one mutation at a time]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1003?rss=1</link>
<description><![CDATA[
<p>Accumulating data suggest that not all human immunodeficiency virus (HIV)-1&ndash;specific immune responses are equally effective at controlling HIV-1 replication. A new study now demonstrates that multiple immune-driven sequence polymorphisms in the highly conserved HIV-1 Gag region of transmitted viruses are associated with reduced viral replication in newly infected humans. These data suggest that targeting these and other conserved viral regions may be the key to developing an effective HIV-1 vaccine.</p>
]]></description>
<dc:creator><![CDATA[Allen, T. M., Altfeld, M.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20080569</dc:identifier>
<dc:title><![CDATA[Crippling HIV one mutation at a time]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1007</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1003</prism:startingPage>
<prism:section>Commentaries</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1009?rss=1">
<title><![CDATA[Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1009?rss=1</link>
<description><![CDATA[
<p>In a study of 114 epidemiologically linked Zambian transmission pairs, we evaluated the impact of human leukocyte antigen class I (HLA-I)&ndash;associated amino acid polymorphisms, presumed to reflect cytotoxic T lymphocyte (CTL) escape in Gag and Nef of the virus transmitted from the chronically infected donor, on the plasma viral load (VL) in matched recipients 6 mo after infection. CTL escape mutations in Gag and Nef were seen in the donors, which were subsequently transmitted to recipients, largely unchanged soon after infection. We observed a significant correlation between the number of Gag escape mutations targeted by specific HLA-B allele&ndash;restricted CTLs and reduced VLs in the recipients. This negative correlation was most evident in newly infected individuals, whose HLA alleles were unable to effectively target Gag and select for CTL escape mutations in this gene. Nef mutations in the donor had no impact on VL in the recipient. Thus, broad Gag-specific CTL responses capable of driving virus escape in the donor may be of clinical benefit to both the donor and recipient. In addition to their direct implications for HIV-1 vaccine design, these data suggest that CTL-induced viral polymorphisms and their associated in vivo viral fitness costs could have a significant impact on HIV-1 pathogenesis.</p>
]]></description>
<dc:creator><![CDATA[Goepfert, P. A., Lumm, W., Farmer, P., Matthews, P., Prendergast, A., Carlson, J. M., Derdeyn, C. A., Tang, J., Kaslow, R. A., Bansal, A., Yusim, K., Heckerman, D., Mulenga, J., Allen, S., Goulder, P. J.R., Hunter, E.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072457</dc:identifier>
<dc:title><![CDATA[Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1017</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1009</prism:startingPage>
<prism:section>Brief Definitive Reports</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1019?rss=1">
<title><![CDATA[IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+ T cells]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1019?rss=1</link>
<description><![CDATA[
<p>We propose a novel role for interleukin (IL) 6 in inducing rapid spontaneous proliferation (SP) of naive CD8<sup>+</sup> T cells, which is a crucial step in the differentiation of colitogenic CD8<sup>+</sup> T cells. Homeostasis of T cells is regulated by two distinct modes of cell proliferation: major histocompatibility complex/antigen&ndash;driven rapid SP and IL-7/IL-15&ndash;dependent slow homeostatic proliferation. Using our novel model of CD8<sup>+</sup> T cell&ndash;dependent colitis, we found that SP of naive CD8<sup>+</sup> T cells is essential for inducing pathogenic cytokine-producing effector T cells. The rapid SP was predominantly induced in mesenteric lymph nodes (LNs) but not in peripheral LNs under the influence of intestinal flora and IL-6. Indeed, this SP was markedly inhibited by treatment with anti&ndash;IL-6 receptor monoclonal antibody (IL-6R mAb) or antibiotic-induced flora depletion, but not by anti&ndash;IL-7R mAb and/or in IL-15&ndash;deficient conditions. Concomitantly with the inhibition of SP, anti&ndash;IL-6R mAb significantly inhibited the induction of CD8<sup>+</sup> T cell&ndash;dependent autoimmune colitis. Notably, the transfer of naive CD8<sup>+</sup> T cells derived from IL-17<sup>&ndash;/&ndash;</sup> mice did not induce autoimmune colitis. Thus, we conclude that IL-6 signaling is crucial for SP under lymphopenic conditions, which subsequently caused severe IL-17&ndash;producing CD8<sup>+</sup> T cell&ndash;mediated autoimmune colitis. We suggest that anti&ndash;IL-6R mAb may become a promising strategy for the therapy of colitis.</p>
]]></description>
<dc:creator><![CDATA[Tajima, M., Wakita, D., Noguchi, D., Chamoto, K., Yue, Z., Fugo, K., Ishigame, H., Iwakura, Y., Kitamura, H., Nishimura, T.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20071133</dc:identifier>
<dc:title><![CDATA[IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+ T cells]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1027</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1019</prism:startingPage>
<prism:section>Brief Definitive Reports</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1029?rss=1">
<title><![CDATA[During negative selection, Nur77 family proteins translocate to mitochondria where they associate with Bcl-2 and expose its proapoptotic BH3 domain]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1029?rss=1</link>
<description><![CDATA[
<p>Apoptosis accompanying negative selection is a central but poorly understood event in T cell development. The Nur77 nuclear steroid receptor and Bim, a proapoptotic BH3-only member of the Bcl-2 family, are two molecules implicated in this process. However, how they relate to each other and how Nur77 induces apoptosis remain unclear. In thymocytes, Nur77 has been shown to induce cell death through a transcriptional-dependent pathway, but in cancer cell lines, Nur77 was reported to induce apoptosis through conversion of Bcl-2 into a killer protein at the mitochondria. Whether this Nur77 transcriptional-independent pathway actually occurs in vivo remains controversial. Using an optimized fractionation protocol for thymocytes, here we report that stimulation of CD4<sup>+</sup>CD8<sup>+</sup> thymocytes results in translocation of Nur77 and its family member Nor-1 to the mitochondria, leading to their association with Bcl-2 and exposure of the Bcl-2 proapoptotic BH3 domain. In two T cell receptor transgenic models of negative selection, F5 and HY, a conformational change of the Bcl-2 molecule in the negatively selected T cell population was similarly observed. Thus, the Nur77 family and Bim pathways converge at mitochondria to mediate negative selection.</p>
]]></description>
<dc:creator><![CDATA[Thompson, J., Winoto, A.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20080101</dc:identifier>
<dc:title><![CDATA[During negative selection, Nur77 family proteins translocate to mitochondria where they associate with Bcl-2 and expose its proapoptotic BH3 domain]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1036</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1029</prism:startingPage>
<prism:section>Brief Definitive Reports</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1037?rss=1">
<title><![CDATA[Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1037?rss=1</link>
<description><![CDATA[
<p>We identify the tumor necrosis factor receptor superfamily 25 (TNFRSF25)/TNFSF15 pair as critical trigger for allergic lung inflammation, which is a cardinal feature of asthma. TNFRSF25 (TNFR25) signals are required to exert T helper cell 2 (Th2) effector function in Th2-polarized CD4 cells and co-stimulate interleukin (IL)-13 production by glycosphingolipid-activated NKT cells. In vivo, antibody blockade of TNFSF15 (TL1A), which is the ligand for TNFR25, inhibits lung inflammation and production of Th2 cytokines such as IL-13, even when administered days after airway antigen exposure. Similarly, blockade of TNFR25 by a dominant-negative (DN) transgene, DN TNFR25, confers resistance to lung inflammation in mice. Allergic lung inflammation&ndash;resistant, NKT-deficient mice become susceptible upon adoptive transfer of wild-type NKT cells, but not after transfer of DN TNFR25 transgenic NKT cells. The TNFR25/TL1A pair appears to provide an early signal for Th2 cytokine production in the lung, and therefore may be a drug target in attempts to attenuate lung inflammation in asthmatics.</p>
]]></description>
<dc:creator><![CDATA[Fang, L., Adkins, B., Deyev, V., Podack, E. R.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072528</dc:identifier>
<dc:title><![CDATA[Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1048</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1037</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1049?rss=1">
<title><![CDATA[TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1049?rss=1</link>
<description><![CDATA[
<p>T helper type 17 (Th17) cells play an important pathogenic function in autoimmune diseases; their regulation, however, is not well understood. We show that the expression of a tumor necrosis factor receptor family member, death receptor 3 (DR3; also known as TNFRSF25), is selectively elevated in Th17 cells, and that TL1A, its cognate ligand, can promote the proliferation of effector Th17 cells. To further investigate the role of the TL1A&ndash;DR3 pathway in Th17 regulation, we generated a TL1A-deficient mouse and found that TL1A<sup>&ndash;/&ndash;</sup> dendritic cells exhibited a reduced capacity in supporting Th17 differentiation and proliferation. Consistent with these data, TL1A<sup>&ndash;/&ndash;</sup> animals displayed decreased clinical severity in experimental autoimmune encephalomyelitis (EAE). Finally, we demonstrated that during EAE disease progression, TL1A was required for the optimal differentiation as well as effector function of Th17 cells. These observations thus establish an important role of the TL1A&ndash;DR3 pathway in promoting Th17 cell function and Th17-mediated autoimmune disease.</p>
]]></description>
<dc:creator><![CDATA[Pappu, B. P., Borodovsky, A., Zheng, T. S., Yang, X., Wu, P., Dong, X., Weng, S., Browning, B., Scott, M. L., Ma, L., Su, L., Tian, Q., Schneider, P., Flavell, R. A., Dong, C., Burkly, L. C.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20071364</dc:identifier>
<dc:title><![CDATA[TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1062</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1049</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1063?rss=1">
<title><![CDATA[Regulation of inflammatory responses by IL-17F]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1063?rss=1</link>
<description><![CDATA[
<p>Although interleukin (IL) 17 has been extensively characterized, the function of IL-17F, which has an expression pattern regulated similarly to IL-17, is poorly understood. We show that like IL-17, IL-17F regulates proinflammatory gene expression in vitro, and this requires IL-17 receptor A, tumor necrosis factor receptor&ndash;associated factor 6, and Act1. In vivo, overexpression of IL-17F in lung epithelium led to infiltration of lymphocytes and macrophages and mucus hyperplasia, similar to observations made in IL-17 transgenic mice. To further understand the function of IL-17F, we generated and analyzed mice deficient in IL-17F or IL-17. IL-17, but not IL-17F, was required for the initiation of experimental autoimmune encephalomyelitis. Mice deficient in IL-17F, but not IL-17, had defective airway neutrophilia in response to allergen challenge. Moreover, in an asthma model, although IL-17 deficiency reduced T helper type 2 responses, IL-17F&ndash;deficient mice displayed enhanced type 2 cytokine production and eosinophil function. In addition, IL-17F deficiency resulted in reduced colitis caused by dextran sulfate sodium, whereas IL-17 knockout mice developed more severe disease. Our results thus demonstrate that IL-17F is an important regulator of inflammatory responses that seems to function differently than IL-17 in immune responses and diseases.</p>
]]></description>
<dc:creator><![CDATA[Yang, X. O., Chang, S. H., Park, H., Nurieva, R., Shah, B., Acero, L., Wang, Y.-H., Schluns, K. S., Broaddus, R. R., Zhu, Z., Dong, C.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20071978</dc:identifier>
<dc:title><![CDATA[Regulation of inflammatory responses by IL-17F]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1075</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1063</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1077?rss=1">
<title><![CDATA[Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1077?rss=1</link>
<description><![CDATA[
<p>Innate immune signaling is critical for the development of protective immunity. Such signaling is, perforce, tightly controlled. Lipoxins (LXs) are eicosanoid mediators that play key counterregulatory roles during infection. The molecular mechanisms underlying LX-mediated control of innate immune signaling are of interest. In this study, we show that LX and aspirin (ASA)-triggered LX (ATL) inhibit innate immune signaling by inducing suppressor of cytokine signaling (SOCS) 2&ndash;dependent ubiquitinylation and proteasome-mediated degradation of TNF receptor&ndash;associated factor (TRAF) 2 and TRAF6, which are adaptor molecules that couple TNF and interleukin-1 receptor/Toll-like receptor family members to intracellular signaling events. LX-mediated degradation of TRAF6 inhibits proinflammatory cytokine production by dendritic cells. This restraint of innate immune signaling can be ablated by inhibition of proteasome function. In vivo, this leads to dysregulated immune responses, accompanied by increased mortality during infection. Proteasomal degradation of TRAF6 is a central mechanism underlying LX-driven immune counterregulation, and a hitherto unappreciated mechanism of action of ASA. These findings suggest a new molecular target for drug development for diseases marked by dysregulated inflammatory responses.</p>
]]></description>
<dc:creator><![CDATA[Machado, F. S., Esper, L., Dias, A., Madan, R., Gu, Y., Hildeman, D., Serhan, C. N., Karp, C. L., Aliberti, J.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072416</dc:identifier>
<dc:title><![CDATA[Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1086</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1077</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1087?rss=1">
<title><![CDATA[Essential role of Notch signaling in effector memory CD8+ T cell-mediated airway hyperresponsiveness and inflammation]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1087?rss=1</link>
<description><![CDATA[
<p>Adoptive transfer of in vivo&ndash;primed CD8<sup>+</sup> T cells or in vitro&ndash;generated effector memory CD8<sup>+</sup> T (T<SUB>EFF</SUB>) cells restores airway hyperresponsiveness (AHR) and airway inflammation in CD8-deficient (CD8<sup>&ndash;/&ndash;</sup>) mice. Examining transcription levels, there was a strong induction of Notch1 in T<SUB>EFF</SUB> cells compared with central memory CD8<sup>+</sup> T cells. Treatment of T<SUB>EFF</SUB> cells with a -secretase inhibitor (GSI) strongly inhibited Notch signaling in these cells, and after adoptive transfer, GSI-treated T<SUB>EFF</SUB> cells failed to restore AHR and airway inflammation in sensitized and challenged recipient CD8<sup>&ndash;/&ndash;</sup> mice, or to enhance these responses in recipient wild-type (WT) mice. These effects of GSI were also associated with increased expression of the Notch ligand Delta1 in T<SUB>EFF</SUB> cells. Treatment of sensitized and challenged WT mice with Delta1-Fc resulted in decreased AHR and airway inflammation accompanied by higher levels of interferon  in bronchoalveolar lavage fluid. These results demonstrate a role for Notch in skewing the T cell response from a T helper (Th)2 to a Th1 phenotype as a consequence of the inhibition of Notch receptor activation and the up-regulation of the Notch ligand Delta1. These data are the first to show a functional role for Notch in the challenge phase of CD8<sup>+</sup> T cell&ndash;mediated development of AHR and airway inflammation, and identify Delta1 as an important regulator of allergic airway inflammation.</p>
]]></description>
<dc:creator><![CDATA[Okamoto, M., Takeda, K., Joetham, A., Ohnishi, H., Matsuda, H., Swasey, C. H., Swanson, B. J., Yasutomo, K., Dakhama, A., Gelfand, E. W.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072200</dc:identifier>
<dc:title><![CDATA[Essential role of Notch signaling in effector memory CD8+ T cell-mediated airway hyperresponsiveness and inflammation]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1097</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1087</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1099?rss=1">
<title><![CDATA[A role for sex chromosome complement in the female bias in autoimmune disease]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1099?rss=1</link>
<description><![CDATA[
<p>Most autoimmune diseases are more common in women than in men. This may be caused by differences in sex hormones, sex chromosomes, or both. In this study, we determined if there was a contribution of sex chromosomes to sex differences in susceptibility to two immunologically distinct disease models, experimental autoimmune encephalomyelitis (EAE) and pristane-induced lupus. Transgenic SJL mice were created to permit a comparison between XX and XY within a common gonadal type. Mice of the XX sex chromosome complement, as compared with XY, demonstrated greater susceptibility to both EAE and lupus. This is the first evidence that the XX sex chromosome complement, as compared with XY, confers greater susceptibility to autoimmune disease.</p>
]]></description>
<dc:creator><![CDATA[Smith-Bouvier, D. L., Divekar, A. A., Sasidhar, M., Du, S., Tiwari-Woodruff, S. K., King, J. K., Arnold, A. P., Singh, R. R., Voskuhl, R. R.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20070850</dc:identifier>
<dc:title><![CDATA[A role for sex chromosome complement in the female bias in autoimmune disease]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1108</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1099</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1109?rss=1">
<title><![CDATA[Bmi1 regulates memory CD4 T cell survival via repression of the Noxa gene]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1109?rss=1</link>
<description><![CDATA[
<p>The maintenance of memory T cells is central to the establishment of immunological memory, although molecular details of the process are poorly understood. In the absence of the polycomb group (PcG) gene <I>Bmi1</I>, the number of memory CD4<sup>+</sup> T helper (Th)1/Th2 cells was reduced significantly. Enhanced cell death of <I>Bmi1</I><sup>&ndash;/&ndash;</sup> memory Th2 cells was observed both in vivo and in vitro. Among various proapoptotic genes that are regulated by Bmi1, the expression of proapoptotic BH3-only protein Noxa was increased in <I>Bmi1</I><sup>&ndash;/&ndash;</sup> effector Th1/Th2 cells. The generation of memory Th2 cells was restored by the deletion of <I>Noxa</I>, but not by <I>Ink4a</I> and <I>Arf</I>. Direct binding of Bmi1 to the <I>Noxa</I> gene locus was accompanied by histone H3-K27 methylation. The recruitment of other PcG gene products and Dnmt1 to the <I>Noxa</I> gene was highly dependent on the expression of Bmi1. In addition, Bmi1 was required for DNA CpG methylation of the <I>Noxa</I> gene. Moreover, memory Th2-dependent airway inflammation was attenuated substantially in the absence of Bmi1. Thus, Bmi1 controls memory CD4<sup>+</sup> Th1/Th2 cell survival and function through the direct repression of the <I>Noxa</I> gene.</p>
]]></description>
<dc:creator><![CDATA[Yamashita, M., Kuwahara, M., Suzuki, A., Hirahara, K., Shinnaksu, R., Hosokawa, H., Hasegawa, A., Motohashi, S., Iwama, A., Nakayama, T.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072000</dc:identifier>
<dc:title><![CDATA[Bmi1 regulates memory CD4 T cell survival via repression of the Noxa gene]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1120</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1109</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1121?rss=1">
<title><![CDATA[Virulent Shigella flexneri subverts the host innate immune response through manipulation of antimicrobial peptide gene expression]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1121?rss=1</link>
<description><![CDATA[
<p>Antimicrobial factors are efficient defense components of the innate immunity, playing a crucial role in the intestinal homeostasis and protection against pathogens. In this study, we report that upon infection of polarized human intestinal cells in vitro, virulent <I>Shigella flexneri</I> suppress transcription of several genes encoding antimicrobial cationic peptides, particularly the human &beta;-defensin hBD-3, which we show to be especially active against <I>S. flexneri</I>. This is an example of targeted survival strategy. We also identify the MxiE bacterial regulator, which controls a regulon encompassing a set of virulence plasmid-encoded effectors injected into host cells and regulating innate signaling, as being responsible for this dedicated regulatory process. In vivo, in a model of human intestinal xenotransplant, we confirm at the transcriptional and translational level, the presence of a dedicated MxiE-dependent system allowing <I>S. flexneri</I> to suppress expression of antimicrobial cationic peptides and promoting its deeper progression toward intestinal crypts. We demonstrate that this system is also able to down-regulate additional innate immunity genes, such as the chemokine CCL20 gene, leading to compromised recruitment of dendritic cells to the lamina propria of infected tissues. Thus, <I>S. flexneri</I> has developed a dedicated strategy to weaken the innate immunity to manage its survival and colonization ability in the intestine.</p>
]]></description>
<dc:creator><![CDATA[Sperandio, B., Regnault, B., Guo, J., Zhang, Z., Stanley, S. L., Sansonetti, P. J., Pedron, T.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20071698</dc:identifier>
<dc:title><![CDATA[Virulent Shigella flexneri subverts the host innate immune response through manipulation of antimicrobial peptide gene expression]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1132</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1121</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1133?rss=1">
<title><![CDATA[C5 deficiency and C5a or C5aR blockade protects against cerebral malaria]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1133?rss=1</link>
<description><![CDATA[
<p>Experimental infection of mice with <I>Plasmodium berghei</I> ANKA (PbA) provides a powerful model to define genetic determinants that regulate the development of cerebral malaria (CM). Based on the hypothesis that excessive activation of the complement system may confer susceptibility to CM, we investigated the role of C5/C5a in the development of CM. We show a spectrum of susceptibility to PbA in a panel of inbred mice; all CM-susceptible mice examined were found to be <I>C5</I> sufficient, whereas all <I>C5</I>-deficient strains were resistant to CM. Transfer of the <I>C5</I>-defective allele from an A/J (CM resistant) onto a C57BL/6 (CM-susceptible) genetic background in a congenic strain conferred increased resistance to CM; conversely, transfer of the <I>C5</I>-sufficient allele from the C57BL/6 onto the A/J background recapitulated the CM-susceptible phenotype. The role of <I>C5</I> was further explored in B10.D2 mice, which are identical for all loci other than <I>C5</I>. <I>C5</I>-deficient B10.D2 mice were protected from CM, whereas <I>C5</I>-sufficient B10.D2 mice were susceptible. Antibody blockade of C5a or C5a receptor (C5aR) rescued susceptible mice from CM. In vitro studies showed that C5a-potentiated cytokine secretion induced by the malaria product <I>P. falciparum</I> glycosylphosphatidylinositol and C5aR blockade abrogated these amplified responses. These data provide evidence implicating <I>C5/</I>C5a in the pathogenesis of CM.</p>
]]></description>
<dc:creator><![CDATA[Patel, S. N., Berghout, J., Lovegrove, F. E., Ayi, K., Conroy, A., Serghides, L., Min-oo, G., Gowda, D. C., Sarma, J. V., Rittirsch, D., Ward, P. A., Liles, W. C., Gros, P., Kain, K. C.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072248</dc:identifier>
<dc:title><![CDATA[C5 deficiency and C5a or C5aR blockade protects against cerebral malaria]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1143</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1133</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1145?rss=1">
<title><![CDATA[Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1145?rss=1</link>
<description><![CDATA[
<p>Bone sialoprotein (BSP) and osteopontin (OPN) are both highly expressed in bone, but their functional specificities are unknown. OPN knockout (<sup>&ndash;/&ndash;</sup>) mice do not lose bone in a model of hindlimb disuse (tail suspension), showing the importance of OPN in bone remodeling. We report that BSP<sup>&ndash;/&ndash;</sup> mice are viable and breed normally, but their weight and size are lower than wild-type (WT) mice. Bone is undermineralized in fetuses and young adults, but not in older (&ge;12 mo) BSP<sup>&ndash;/&ndash;</sup> mice. At 4 mo, BSP<sup>&ndash;/&ndash;</sup> mice display thinner cortical bones than WT, but greater trabecular bone volume with very low bone formation rate, which indicates reduced resorption, as confirmed by lower osteoclast surfaces. Although the frequency of total colonies and committed osteoblast colonies is the same, fewer mineralized colonies expressing decreased levels of osteoblast markers form in BSP<sup>&ndash;/&ndash;</sup> versus WT bone marrow stromal cultures. BSP<sup>&ndash;/&ndash;</sup> hematopoietic progenitors form fewer osteoclasts, but their resorptive activity on dentin is normal. Tail-suspended BSP<sup>&ndash;/&ndash;</sup> mice lose bone in hindlimbs, as expected. In conclusion, BSP deficiency impairs bone growth and mineralization, concomitant with dramatically reduced bone formation. It does not, however, prevent the bone loss resulting from loss of mechanical stimulation, a phenotype that is clearly different from OPN<sup>&ndash;/&ndash;</sup> mice.</p>
]]></description>
<dc:creator><![CDATA[Malaval, L., Wade-Gueye, N. M., Boudiffa, M., Fei, J., Zirngibl, R., Chen, F., Laroche, N., Roux, J.-P., Burt-Pichat, B., Duboeuf, F., Boivin, G., Jurdic, P., Lafage-Proust, M.-H., Amedee, J., Vico, L., Rossant, J., Aubin, J. E.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20071294</dc:identifier>
<dc:title><![CDATA[Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1153</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1145</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1155?rss=1">
<title><![CDATA[The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1155?rss=1</link>
<description><![CDATA[
<p>Semaphorins are a large family of evolutionarily conserved morphogenetic molecules originally identified for their repelling role in axonal guidance. Intriguingly, semaphorins have recently been implicated in cancer progression (Neufeld, G., T. Lange, A. Varshavsky, and O. Kessler. 2007. <I>Adv. Exp. Med. Biol.</I> 600:118&ndash;131). In particular, semaphorin 3B (SEMA3B) is considered a putative tumor suppressor, and yet we found that it is expressed at high levels in many invasive and metastatic human cancers. By investigating experimental tumor models, we confirmed that SEMA3B expression inhibited tumor growth, whereas metastatic dissemination was surprisingly increased. We found that SEMA3B induced the production of interleukin (IL) 8 by tumor cells by activating the p38&ndash;mitogen-activated protein kinase pathway in a neuropilin 1&ndash;dependent manner. Silencing the expression of endogenous SEMA3B in tumor cells impaired IL-8 transcription. The release of IL-8, in turn, induced the recruitment of tumor-associated macrophages and metastatic dissemination to the lung, which could be rescued by blocking IL-8 with neutralizing antibodies. In conclusion, we report that SEMA3B exerts unexpected functions in cancer progression by fostering a prometastatic environment through elevated IL-8 secretion and recruitment of macrophages coupled to the suppression of tumor growth.</p>
]]></description>
<dc:creator><![CDATA[Rolny, C., Capparuccia, L., Casazza, A., Mazzone, M., Vallario, A., Cignetti, A., Medico, E., Carmeliet, P., Comoglio, P. M., Tamagnone, L.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072509</dc:identifier>
<dc:title><![CDATA[The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1171</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1155</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1173?rss=1">
<title><![CDATA[T cell receptor-instructed {alpha}{beta} versus {gamma}{delta} lineage commitment revealed by single-cell analysis]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1173?rss=1</link>
<description><![CDATA[
<p>&beta; and  T cell lineages develop in the thymus from a common precursor. It is unclear at which stage of development commitment to these lineages takes place and in which way T cell receptor signaling contributes to the process. Recently, it was demonstrated that strong TCR signals favor  lineage development, whereas weaker TCR signals promote &beta; lineage fate. Two models have been proposed to explain these results. The first model suggests that commitment occurs after TCR expression and TCR signaling directly instructs lymphocytes to adopt one or the other lineage fate. The second model suggests that commitment occurs before TCR expression and that TCR signaling merely confirms the lineage choice. By tracing the fate of single T cell precursors, this study shows that there is no commitment to either the &beta; or  lineage before TCR expression and that modulation of TCR signaling in progeny of a single TCR-expressing cell changes lineage commitment.</p>
]]></description>
<dc:creator><![CDATA[Kreslavsky, T., Garbe, A. I., Krueger, A., von Boehmer, H.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072425</dc:identifier>
<dc:title><![CDATA[T cell receptor-instructed {alpha}{beta} versus {gamma}{delta} lineage commitment revealed by single-cell analysis]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1186</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1173</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1187?rss=1">
<title><![CDATA[The stream of precursors that colonizes the thymus proceeds selectively through the early T lineage precursor stage of T cell development]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1187?rss=1</link>
<description><![CDATA[
<p>T cell development in the thymus depends on continuous colonization by hematopoietic precursors. Several distinct T cell precursors have been identified, but whether one or several independent precursor cell types maintain thymopoiesis is unclear. We have used thymus transplantation and an inducible lineage-tracing system to identify the intrathymic precursor cells among previously described thymus-homing progenitors that give rise to the T cell lineage in the thymus. Extrathymic precursors were not investigated in these studies. Both approaches show that the stream of T cell lineage precursor cells, when entering the thymus, selectively passes through the early T lineage precursor (ETP) stage. Immigrating precursor cells do not exhibit characteristics of double-negative (DN) 1c, DN1d, or DN1e stages, or of populations containing the common lymphoid precursor 2 (CLP-2) or the thymic equivalent of circulating T cell progenitors (CTPs). It remains possible that an unknown hematopoietic precursor cell or previously described extrathymic precursors with a CLP, CLP-2, or CTP phenotype feed into T cell development by circumventing known intrathymic T cell lineage progenitor cells. However, it is clear that of the known intrathymic precursors, only the ETP population contributes significant numbers of T lineage precursors to T cell development.</p>
]]></description>
<dc:creator><![CDATA[Benz, C., Martins, V. C., Radtke, F., Bleul, C. C.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072168</dc:identifier>
<dc:title><![CDATA[The stream of precursors that colonizes the thymus proceeds selectively through the early T lineage precursor stage of T cell development]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1199</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1187</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1201?rss=1">
<title><![CDATA[MR1 uses an endocytic pathway to activate mucosal-associated invariant T cells]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1201?rss=1</link>
<description><![CDATA[
<p>Like CD1d-restricted <I>i</I>NKT cells, mucosal-associated invariant T cells (MAITs) are "innate" T cells that express a canonical TCR chain, have a memory phenotype, and rapidly secrete cytokines upon TCR ligation. Unlike <I>i</I>NKT cells, MAIT cells require the class Ib molecule MHC-related protein I (MR1), B cells, and gut flora for development and/or expansion, and they preferentially reside in the gut lamina propria. Evidence strongly suggests that MAIT cell activation is ligand-dependent, but the nature of MR1 ligand is unknown. In this study, we define a mechanism of endogenous antigen presentation by MR1 to MAIT cells. MAIT cell activation was dependent neither on a proteasome-processed ligand nor on the chaperoning by the MHC class I peptide loading complex. However, MAIT cell activation was enhanced by overexpression of MHC class II chaperones Ii and DM and was strikingly diminished by silencing endogenous Ii. Furthermore, inhibiting the acidification of the endocytic compartments reduced MR1 surface expression and ablated MAIT cell activation. The importance of the late endosome for MR1 antigen presentation was further corroborated by the localization of MR1 molecules in the multivesicular endosomes. These findings demonstrate that MR1 traffics through endocytic compartments, thereby allowing MAIT cells to sample both endocytosed and endogenous antigens.</p>
]]></description>
<dc:creator><![CDATA[Huang, S., Gilfillan, S., Kim, S., Thompson, B., Wang, X., Sant, A. J., Fremont, D. H., Lantz, O., Hansen, T. H.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072579</dc:identifier>
<dc:title><![CDATA[MR1 uses an endocytic pathway to activate mucosal-associated invariant T cells]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1211</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1201</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1213?rss=1">
<title><![CDATA[IL-15R{alpha} chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1213?rss=1</link>
<description><![CDATA[
<p>Natural killer (NK) cells are innate immune effectors that mediate rapid responses to viral antigens. Interleukin (IL)-15 and its high affinity IL-15 receptor, IL-15R, support NK cell homeostasis in resting animals via a novel trans presentation mechanism. To better understand how IL-15 and IL-15R support NK cell activation during immune responses, we have used sensitive assays for detecting native IL-15 and IL-15R proteins and developed an assay for detecting complexes of these proteins. We find that IL-15 and IL-15R are preassembled in complexes within the endoplasmic reticulum/Golgi of stimulated dendritic cells (DCs) before being released from cells. IL-15R is required for IL-15 production by DCs, and IL-15 that emerges onto the cell surface of matured DCs does not bind to neighboring cells expressing IL-15R. We also find that soluble IL-15&ndash;IL-15R complexes are induced during inflammation, but membrane-bound IL-15&ndash;IL-15R complexes, rather than soluble complexes, support NK cell activation in vitro and in vivo. Finally, we provide in vivo evidence that expression of IL-15R specifically on DCs is critical for trans presenting IL-15 and activating NK cells. These studies define an unprecedented cytokine&ndash;receptor biosynthetic pathway in which IL-15R serves as a chaperone for IL-15, after which membrane-bound IL-15R&ndash;IL-15 complexes activate NK cells via direct cell&ndash;cell contact.</p>
]]></description>
<dc:creator><![CDATA[Mortier, E., Woo, T., Advincula, R., Gozalo, S., Ma, A.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20071913</dc:identifier>
<dc:title><![CDATA[IL-15R{alpha} chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1225</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1213</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1227?rss=1">
<title><![CDATA[ATF4 is an oxidative stress-inducible, prodeath transcription factor in neurons in vitro and in vivo]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1227?rss=1</link>
<description><![CDATA[
<p>Oxidative stress is pathogenic in neurological diseases, including stroke. The identity of oxidative stress&ndash;inducible transcription factors and their role in propagating the death cascade are not well known. In an in vitro model of oxidative stress, the expression of the bZip transcription factor activating transcription factor 4 (ATF4) was induced by glutathione depletion and localized to the promoter of a putative death gene in neurons. Germline deletion of ATF4 resulted in a profound reduction in oxidative stress&ndash;induced gene expression and resistance to oxidative death. In neurons, ATF4 modulates an early, upstream event in the death pathway, as resistance to oxidative death by ATF4 deletion was associated with decreased consumption of the antioxidant glutathione. Forced expression of ATF4 was sufficient to promote cell death and loss of glutathione. In ATF4<sup>&ndash;/&ndash;</sup> neurons, restoration of ATF4 protein expression reinstated sensitivity to oxidative death. In addition, ATF4<sup>&ndash;/&ndash;</sup> mice experienced significantly smaller infarcts and improved behavioral recovery as compared with wild-type mice subjected to the same reductions in blood flow in a rodent model of ischemic stroke. Collectively, these findings establish ATF4 as a redox-regulated, prodeath transcriptional activator in the nervous system that propagates death responses to oxidative stress in vitro and to stroke in vivo.</p>
]]></description>
<dc:creator><![CDATA[Lange, P. S., Chavez, J. C., Pinto, J. T., Coppola, G., Sun, C.-W., Townes, T. M., Geschwind, D. H., Ratan, R. R.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20071460</dc:identifier>
<dc:title><![CDATA[ATF4 is an oxidative stress-inducible, prodeath transcription factor in neurons in vitro and in vivo]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1242</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1227</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://www.jem.org/cgi/content/short/205/5/1243?rss=1">
<title><![CDATA[Phospholipase C-{gamma}2 and Vav cooperate within signaling microclusters to propagate B cell spreading in response to membrane-bound antigen]]></title>
<link>http://www.jem.org/cgi/content/short/205/5/1243?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Weber, M., Treanor, B., Depoil, D., Shinohara, H., Harwood, N. E., Hikida, M., Kurosaki, T., Batista, F. D.]]></dc:creator>
<dc:date>2008-05-12</dc:date>
<dc:identifier>info:doi/10.1084/jem.20072619040408c</dc:identifier>
<dc:title><![CDATA[Phospholipase C-{gamma}2 and Vav cooperate within signaling microclusters to propagate B cell spreading in response to membrane-bound antigen]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>205</prism:volume>
<prism:endingPage>1243</prism:endingPage>
<prism:publicationDate>2008-05-12</prism:publicationDate>
<prism:startingPage>1243</prism:startingPage>
<prism:section>Corrections</prism:section>
</item>

</rdf:RDF>